<DOC>
	<DOC>NCT01838499</DOC>
	<brief_summary>The purpose of this study is to gain initial evidence for the safety, tolerability and efficacy of MEDI8968 for the treatment of subjects with moderate to severe hidradenitis suppurativa</brief_summary>
	<brief_title>Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa</brief_title>
	<detailed_description />
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<criteria>Hidradenitis suppurativa (HS) (moderate to severe) Diagnosis of HS for at least 1 year At least 5 active inflammatory lesions in at least 2 locations On a stable dose of antibiotics and/or analgesics for at least 4 weeks (if already taking these medications) Average pain score of 39. History of cyclic neutropenia Laboratory assessment abnormalities Underlying disorder considered unsuitable for inclusion Other skin diseases that may interfere with HS assessment Pregnancy or planning for pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>